Fuente: FierceBiotech Six weeks after Intellia Therapeutics reported that it met its primary endpoint in a phase 3 trial of its in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) for patients with hereditary angioedema (HAE), the company released additional positive data showing that the study also met its secondary endpoints with statistical and clinical significance.